References
- Kerbel R S, Kamen B A. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4: 423–436
- Gasparini G. Metronomic scheduling: the future of chemotherapy?. Lancet Oncol 2001; 2: 733–740
- Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anti-Cancer Drugs 2003; 14: 13–19
- Bocci G, Francia G, Man S, Lawler J, Kerbel R S. Thrombospondin-1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 2003; 100: 12917–12922
- Colleoni M, Rocca A, Sandri M T, Zorzino L, Masci G, Nolè F, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002; 13: 73–80
- Glode L M, Barqawi A, Crighton F, Crawford E D, Kerbel R S. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 2003; 98: 1643–1648
- Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300: 1155–1159
- Anderson K C. Moving disease biology from the laboratory to the clinic. Semin Oncol 2002; 6: 17–20
- Kaufmann H, Raderer M, Wöhrer S, Püspök A, Bankier A, Zielinski C, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004; 104: 2269–2271
- Hu L, Shi Y, Hsu J H, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cell. Blood 2003; 101: 3126–3135
- Raje N, Kumar S, Hideshima T, Ishitsuka K, Chauhan D, Mitsiades C, et al. Combination of the mTOR inhibitor Rapamycin and Revlimid™ (CC-5013) has synergistic activity in multiple myeloma. Blood 2004; 104: 4188–4193
- Portier M, Zhang X G, Caron E, Lu Z Y, Bataille R, Klein B. γ-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood 1993; 81: 3076–3082